San Francisco, CA – [Current Date] – In a development that underscores the complexities of rare disease drug development, Rafael Holdings subsidiary, Cyclo Therapeutics, is pressing forward with plans to seek US regulatory approval for its investigational therapy, Trappsol Cyclo, for Niemann-Pick disease type C (NPC). This ambitious move comes despite the drug failing to meet its primary endpoint in the pivotal Phase III TransportNPC study. The company is banking on compelling secondary endpoint data and subgroup analyses, which suggest a potential benefit in specific patient populations, to sway regulatory bodies. If successful, Trappsol Cyclo could represent the third drug to receive approval for this devastating and rare metabolic disorder.
The Challenge of Niemann-Pick Type C: A Rare Metabolic Enigma
Niemann-Pick disease type C (NPC) is a rare, inherited metabolic disorder that presents a significant challenge to both patients and the medical community. The fundamental issue in NPC lies in the body’s inability to effectively transport lipids, particularly cholesterol, within cells. This malfunction leads to a toxic accumulation of these fatty substances in various organs, most notably the brain, liver, and spleen. The progressive nature of NPC results in a constellation of debilitating symptoms, including severe neurological deficits, liver disease, and ultimately, a significantly shortened lifespan.
The neurological manifestations of NPC are particularly devastating. Patients often experience progressive ataxia (loss of coordination), dysarthria (difficulty speaking), dysphagia (difficulty swallowing), and cognitive decline. As the disease advances, individuals may lose the ability to walk, communicate, and perform basic life functions, placing an immense burden on caregivers and necessitating extensive medical support. The disease’s rarity, with estimated incidence rates ranging from 1 in 100,000 to 1 in 150,000 live births, complicates research efforts and the development of effective treatments. Historically, therapeutic options have been limited, with a significant unmet medical need persisting for patients and their families.
Trappsol Cyclo’s Journey: From Promising Candidate to Regulatory Crossroads
Cyclo Therapeutics’ investigational therapy, Trappsol Cyclo, is an intravenous formulation of hydroxypropyl-β-cyclodextrin. Cyclodextrins are cyclic oligosaccharides that have the ability to encapsulate and solubilize a wide range of molecules, including cholesterol. The therapeutic hypothesis behind Trappsol Cyclo is that by facilitating the transport of cholesterol out of cells, it can mitigate the toxic accumulation characteristic of NPC.
The Phase III TransportNPC study (NCT04860960) was designed to rigorously evaluate the efficacy and safety of Trappsol Cyclo in patients with NPC. The study enrolled 94 patients and employed a complex design that included a placebo-controlled arm and an open-label arm for infants up to three years of age. Patients in the placebo-controlled arm received either a biweekly intravenous dose of Trappsol Cyclo or a placebo over a 96-week period. The primary objective of the study was to assess the drug’s impact on key functional domains of NPC, specifically focusing on fine motor skills, speech, swallowing, and ambulation – all critical indicators of disease progression and quality of life.
The study’s primary endpoint was designed to measure the change from baseline in the four-domain NPC Clinical Severity Scale (4DNPCSS). This scale is a composite measure intended to capture the multifaceted nature of NPC’s impact on a patient’s daily functioning. While the study did observe a favorable trend with Trappsol Cyclo, the mean, placebo-adjusted change on the 4DNPCSS was 0.81 points. Although this suggests a potential positive effect, it did not reach statistical significance, meaning the TransportNPC study ultimately missed its primary endpoint. This outcome presents a significant hurdle for the drug’s regulatory path.
Unveiling Promising Subgroup Data and Survival Benefits
Despite the setback with the primary endpoint, the TransportNPC study yielded several encouraging secondary findings and subgroup analyses that Cyclo Therapeutics believes provide a compelling rationale for continued regulatory pursuit.
One of the most significant observations was the impact of Trappsol Cyclo in a specific subset of patients who were receiving background treatment with existing NPC therapies. These patients were concurrently being treated with either Zavesca (miglustat), a drug approved to lower fat and sugar buildup, or Aqneursa (levacetylleucine / N-acetyl-L-leucine), a neuroprotective medicine. In this particular patient group, Trappsol Cyclo demonstrated a marked reduction in disease progression. Over the 96-week study period, patients receiving Trappsol Cyclo alongside these other therapies experienced a 71% slower rate of disease progression compared to placebo. This translated to a more substantial 1.11-point change on the 4DNPCSS scale, a figure that, while not the primary endpoint, indicates a potentially meaningful clinical benefit for this subgroup. This finding suggests a possible synergistic effect between Trappsol Cyclo and other therapeutic approaches for NPC.
Beyond functional improvements, Trappsol Cyclo also exhibited a notable overall survival (OS) benefit. By comparing treated individuals to matched external controls with similar disease characteristics and progression, Cyclo Therapeutics observed an impressive 85% reduction in the risk of death among patients receiving Trappsol Cyclo. This survival advantage was further amplified in a secondary analysis that incorporated additional matched historical cohorts from published natural history studies. In this expanded analysis, the risk reduction in mortality rose to an even more significant 94%. The substantial impact on survival is a critical consideration for regulators, particularly in the context of a life-threatening disease like NPC where limited treatment options exist.
Furthermore, the safety and tolerability profile of Trappsol Cyclo in the TransportNPC study was generally favorable. Patients generally tolerated the drug well, with no significant differences observed in the rates of serious adverse events between the Trappsol Cyclo treatment arm and the placebo arm. Importantly, only one patient discontinued treatment due to a treatment-related side effect, suggesting a manageable safety profile. This favorable tolerability is a crucial factor for any drug intended for long-term use in patients with chronic conditions.
Official Responses and the Path Forward
The decision by Cyclo Therapeutics and its parent company, Rafael Holdings, to proceed with regulatory submissions despite missing the primary endpoint reflects a strategic assessment of the totality of the data. Karen Mullen, Chief Medical Officer of Rafael Holdings, has articulated the company’s perspective, stating that the data collected from the TransportNPC trial presents a "compelling rationale" to continue the development of Trappsol Cyclo for NPC. This rationale appears to be rooted in the significant findings from the subgroup analyses and the survival data, which the company believes outweigh the failure to meet the primary endpoint on its own.
Rafael Holdings has announced its intention to submit a New Drug Application (NDA) for Trappsol Cyclo to the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2026. This timeline suggests that the company is actively compiling the necessary documentation and preparing for the rigorous review process. The FDA’s evaluation will likely focus heavily on the subgroup data, survival benefit, and safety profile, weighing these against the missed primary endpoint. The agency’s decision will be a crucial indicator of how regulatory bodies interpret positive secondary outcomes in the context of a missed primary endpoint for rare disease therapies.
Implications for the NPC Treatment Landscape
The potential approval of Trappsol Cyclo would have significant implications for the treatment landscape of Niemann-Pick disease type C. Currently, the market for NPC therapies is relatively limited. The existing approved drugs include Zevra Therapeutics’ Miplyffa (arimoclomol) and IntraBio’s Aqneursa (levacetylleucine). If Trappsol Cyclo receives regulatory greenlight, it would join this select group, offering another therapeutic option for patients and their families.
The presence of multiple treatment options, even if each has its own nuances and limitations, is generally beneficial for patients with rare diseases. It provides physicians with more tools to tailor treatment strategies to individual patient needs and potentially allows for combination therapies, as suggested by the positive subgroup data for Trappsol Cyclo.
Beyond Trappsol Cyclo, the NPC pipeline is not entirely barren. Dutch biotech Azafaros is actively exploring the potential of its candidate, nizubaglustat, in ongoing clinical trials. Nizubaglustat is being investigated in both Phase III (NAVIGATE, NCT07082725) and Phase II (PRISMA, NCT07399704) studies. The progress of these investigational therapies highlights the continued scientific interest and investment in developing treatments for NPC.
The case of Trappsol Cyclo also raises broader questions about the regulatory pathways for drugs targeting rare and severe diseases. While endpoints are crucial for demonstrating efficacy, the inherent challenges in conducting large-scale, statistically powered trials for ultra-rare conditions can sometimes make it difficult to meet traditional endpoint criteria. The FDA, and other regulatory agencies, often consider the totality of evidence, including surrogate endpoints, survival data, and the severity of the unmet medical need, when evaluating drug applications for rare diseases. The eventual decision on Trappsol Cyclo could set a precedent for how similar situations are handled in the future, potentially influencing how the industry approaches clinical trial design and regulatory strategy for rare disease therapeutics.
In conclusion, the journey of Trappsol Cyclo towards potential FDA approval is a complex narrative of scientific innovation, clinical trial outcomes, and strategic regulatory engagement. While the failure to meet its primary endpoint in the TransportNPC study presents a significant challenge, the compelling secondary data, particularly the observed survival benefit and the positive impact in a specific patient subgroup, provides a strong foundation for Cyclo Therapeutics’ pursuit. The coming years will be critical in determining whether Trappsol Cyclo can overcome these hurdles and become a vital new therapeutic option for individuals battling the devastating effects of Niemann-Pick type C.
About the Author
